BCG September 14, 2023
Key Takeaways
Three new provisions concerning Medicare prescription drug prices have major ramifications for companies and the broader health care ecosystem.
- Companies will need to evolve their R&D strategies and capabilities in portfolio prioritization, clinical development, financial considerations, and real-world evidence.
- The IRA will also affect payers, patients, and providers, and therefore may have knock-on effects that need to be considered as well.
- Although the full ramifications of the IRA won’t be known for quite a while, companies need to start planning for potential impacts now.
The Inflation Reduction Act (IRA) of 2022 constitutes a major legislative effort to address drug pricing and Medicare expenditure. By now, most industry executives and investors have...
Today's Sponsors
Today's Sponsor